You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨基石藥業大跌超12%,折讓15%配股籌資2.35億
格隆匯 04-02 09:44
基石藥業(2616.HK)盤初大跌,一度跌超12%至3港元,股價創2月25日以來新低。消息面上,基石藥業宣佈配售8000萬股新股,佔擴大後股本約5.86%;每股配售價2.933港元,較昨日收市價3.45港元折讓14.99%,集資約2.35億港元。公司稱,配售所得款項淨額2.32億港元中,90%用於與集團“管線2.0”中的資產,尤其是CS5001(一款處於臨牀階段的ROR1 ADC(潛在同類最佳ROR1 ADC)),以及CS2009(一款靶向PD-1、VEGFA及CTLA-4的三特異性分子,潛在同類首創/同類最優的下一代腫瘤免疫骨架)有關的進一步研發;餘下淨額於適當時用於其他一般公司用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account